A large clinical study in recurrent GBM showed that Optune was as effective as chemotherapy, in certain quality of life measures, with people self-reporting*: Better quality of life. For more than 15 years, Novocure has performed research and published multiple peer-reviewed articles with preclinical data in more than 15 different solid tumor types in culture and eight different tumor models in vivo. Novocure ($7 billion, -20% YTD) is an oncology company that offers a novel therapy called Tumor Treating Fields, which uses electric fields to … Draft material that is patient-focused, explaining the clinical trials to … … Our mechanism of action is broadly applicable across a variety of solid tumors. Please click here to access it. Brief Summary: The study is a prospective, randomized controlled phase III trial, to test the efficacy, safety and neurocognitive outcomes of advanced NSCLC patients, following stereotactic radiosurgery (SRS) for 1-10 brain metastases, treated with NovoTTF-100M compared to supportive treatment alone. Novocure is developing TTFields for different cancer diseases, such as: pancreatic cancer, ovarian cancer, lung cancer, mesothelioma and brain metastasis. About brain metastases: Metastatic cancer is cancer that has spread from the place where it first started to another place in the body. He conducts 20 clinical trials in ovarian cancer per year and was an investigator in Novocure’s phase 2 pilot study in recurrent ovarian cancer, INNOVATE. We pioneer a profoundly different approach to treating cancer called Tumor Treating Fields. NovoCure announced today that it has entered a clinical trial collaboration agreement with Merck.Together, the companies will develop Tumor Treating Fields with Merck’s anti-PD-1 therapy, Keytruda for the treatment of non-small cell lung cancer (NSCLC). The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of Tumor Treating Fields (TTFields) in combination with gemcitabine and nab-paclitaxel, for front line treatment of locally-advanced pancreatic adenocarcinoma.The device is an experimental, portable, battery operated device for chronic administration of alternating electric fields (termed … Tumor Treating Fields (TTFields) are low intensity alternating electric fields tuned to disrupt the division process of cancer cells. Professor Yoram Palti founded Novocure in 2000. Cancer type: Brain metastases from non-small cell lung cancer (Phase 3 pivotal). About ovarian cancer: In the U.S., ovarian cancer ranks fifth in cancer deaths among women, accounting for more deaths than any other cancer of the female reproductive system. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in mesothelioma, brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and liver cancer. The study posted an overall survival of 18.2 months in people who received NovoTTF … Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information. clinical trials Our mechanism of action is broadly applicable across a variety of solid tumors. Work on increasing awareness of Novocure clinical trials by coordinating campaigns in medical journals, and other non-personal media. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer and glioblastoma. Novocure’s Chief Science Officer and Head of Research and Development Eilon Kirson, MD, PhD was one of the first employees to join the company in 2002. For more information on our ongoing clinical trials, visit novocuretrial.com and clinicaltrials.gov. Novocure is the sponsor of clinical trials testing TTFields in several cancers. Headquartered in Jersey, Novocure … Description: The Clinical Trial Associate supports the Clinical Trial Manager and Study Team with all operational and trial related activities from study start-up to close out.. About hepatocellular cancer: Liver cancer is a leading cause of cancer deaths worldwide and is the seventh leading cause of cancer deaths annually in the U.S. Seattle Clinical Trial Associate, ROW - WA, 98119. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and liver cancer. clinical trials Novocure continues to test Tumor Treating Fields against a broad range of solid tumor types. … We sponsor clinical trials of Tumor Treating Fields in several cancer types. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer and … Novocure is developing TTFields for different cancer diseases. Novocure's commercialized products are approved for the treatment of adult patients with glioblastoma and malignant pleural mesothelioma. Novocure is the sponsor of clinical trials testing TTFields in several cancers. … This information is for medical, and scientific and educational purposes only. We have revised our Privacy Policy that is in effect as of May 25, 2018. Novocure is the sponsor of clinical trials testing TTFields in several cancers. Novocure Clinical Trial Investigator Professor Ignace Vergote has dedicated his 32-year career to investigating treatment options and striving to improve survival in gynecologic cancers. Pancreatic cancer is the only major cancer with a five-year relative survival rate in the single digits, at just 8 percent. Advancing our clinical pipeline in indications with significant unmet need. Patients should always consult with their treating physician about their treatment options. the incidence of ovarian cancer is approximately 22,500 new cases annually in the u.S., approximately 68,000 new cases annually in Europe, and approximately 10,000 new cases Here at Novocure, cancer patients and their families are – and have always been – at the core of our mission. Our research shows that Tumor Treating Fields can have an anti-mitotic effect in 18 different solid tumor types in culture and in eight in vivo tumor models, including some of the most aggressive forms of cancer. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, … Novocure has ongoing or completed clinical trials and is further expanding its efforts into several other solid tumor indications - non-small cell lung cancer, pancreatic cancer, ovarian cancer and other types … Novocure's program centered on an 80-person clinical trial, the data from which persuaded FDA to approve the device under its rare disease pathway, HDE. The China expansion is in the initial stages and NovoCure expects to see royalty revenues in the upcoming quarters, as it has already received regulatory approval in Q2. Ovarian cancer incidence increases with age, and the median age at time of diagnosis is 63 years old. By continuing to browse the site you are agreeing to accept our use of cookies. Novocure's program centered on an 80-person clinical trial, the data from which persuaded FDA to approve the device under its rare disease pathway, HDE. Meet our leaders, who have extensive experience across oncology, biotechnology and medical device industries. We are committed to advancing the science of Tumor Treating Fields across a broad spectrum of solid tumors and bringing our treatment to cancer patients who can benefit from our therapy. “There are few possibilities to treat these patients,” … We expect our colleagues to excel, and in return, we invest in their professional growth and personal well-being. This is a full-time, exempt, field-based position that reports to the Clinical Trial … TTFields. Novocure’s commercialized products are approved for the treatment of adult patients with glioblastoma and malignant pleural mesothelioma. The exact incidence of brain metastases is unknown, but it has been estimated that 98,000 to 170,000 new cases are diagnosed in the United States each year. The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of TTFields, using the NovoTTF-100L System, concurrent with standard therapies for stage 4 NSCLC patients, following progression while on or after platinum based treatment.The device is an experimental, portable, battery operated device for chronic administration of alternating electric fields … The study posted an overall … The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of Tumor Treating Fields (TTFields) concomitant with weekly paclitaxel for the treatment of recurrent ovarian cancer. … For more information on our ongoing clinical trials, visit novocuretrial.com and clinicaltrials… Tumor Treating Fields (TTFields) are low intensity alternating electric fields tuned to disrupt the division process of cancer cells. A free inside look at Novocure salary trends based on 24 salaries wages for 20 jobs at Novocure. While overall cancer incidence and death rates are declining, the incidence and death rates for pancreatic cancer are increasing. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer and gastric cancer. Tumor Treating Fields (TTFields) are low intensity alternating electric fields tuned to disrupt the division process of cancer cells. We expect our colleagues to excel, and in return, we invest in their professional growth and … Brain metastases occur in roughly 15% of all cancer patients, and we believe that approximately 40% of brain metastases are a result of NSCLC. We seek high performers who thrive in fast-paced environments and are inspired by making a difference in cancer care. The five-year survival rate with existing standards of care is less than 18%. Salaries posted anonymously by Novocure employees. We have since accomplished many significant milestones. We believe we have gained a deep understanding of the underlying mechanism of action and the multiple pathways through which Tumor Treating Fields exert their effects within dividing cancer cells. He conducts 20 clinical trials in ovarian cancer per year and was an investigator in Novocure’s phase 2 pilot study in recurrent ovarian cancer, INNOVATE. Seattle Clinical Trial Associate, ROW - WA, 98119. The science of Tumor Treating Fields extends beyond glioblastoma. A large clinical study in recurrent GBM showed that Optune was as effective as chemotherapy, in certain quality of life measures, with people self-reporting*: Better quality of life. Interventional (Clinical Trial) Estimated Enrollment : 30 participants: Allocation: Non-Randomized: Intervention Model: Parallel Assignment: Intervention Model Description: Device: NovoCure … In metastasis, cancer cells break away from the primary cancer, travel through the blood or lymph system, and form new, metastatic tumors in other parts of the body. Approximately 214,000 new cases of NSCLC are diagnosed in the U.S. each year, approximately 350,000 new cases are diagnosed annually in Europe, and approximately 95,000 new cases are diagnosed annually in Japan. Novocure maintains this website in order to assist patients, their family members and caregivers in accessing clinical trial sites for potential participation in ongoing trials. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer … About pancreatic cancer: Pancreatic cancer is one of the most lethal cancers and is the third most frequent cause of death from cancer in the United States. The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of Tumor Treating Fields (TTFields) concomitant with weekly paclitaxel for the treatment of … Patient images reflect the health status of the patients at the time each photo or video was taken. Tumor Treating Fields (TTFields) are low intensity alternating electric fields tuned to disrupt the division process of cancer cells. TTFields is experimental for all indications mentioned in those clinical trials and has not been approved for their treatment. Tumor Treating Fields has not been approved by the U.S. Food and Drug Administration for commercial use in these indications. Novocure continues to test Tumor Treating Fields against a broad range of solid tumor types. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell … Eilon Kirson, Novocure’s former Chief Science Officer and Head of Research and Development, visited Dr. Vymazal in 2004 at Na Homolce Hospital in Prague, where Dr. Vymazal worked as a clinical neurologist and radiologist, to discuss running a clinical trial … If you require further information and/or do not wish to have cookies placed when using the site, review the Cookies section of our Website Privacy Policy or visit www.allaboutcookies.org. In China, the company has partnered with biopharmaceutical firm Zai Lab (NASDAQ: ZLAB) to streamline distribution and accelerate clinical trial enrollment. Salaries posted anonymously by Novocure employees. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer and … For the most up-to-date clinical trial information, including protocol details, please visit the U.S. National Institutes of Health’s website at clinicaltrials.gov. In China, the company has partnered with biopharmaceutical firm Zai Lab (NASDAQ: ZLAB) to streamline distribution and accelerate clinical trial enrollment. Brief Summary: The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of TTFields, using the NovoTTF-100L System, concurrent with standard therapies … Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, … Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in mesothelioma, brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and liver cancer. This website intends to use cookies to improve the site and your experience. Additional investigator-sponsored trials are also ongoing. On this site, videos and images identified as Optune users, caregivers or healthcare professionals depict actual patients, caregivers and healthcare professionals. Novocure Vulnerability Disclosure Process. TTFields is currently being tested for other cancers in various clinical trials, presented in this website. The TRIDENT trial (also known as the “EF-32 trial”) is a randomized, controlled study, testing the safety and efficacy of Tumor Treating Fields (TTFields) from the Optune ® System [About TTFields] together … The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of Tumor Treating Fields (TTFields) in combination with gemcitabine and nab-paclitaxel, for … The device is an experimental, portable, battery operated device for chronic administration of … Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer and … Cancer type: Non-small cell lung cancer (Phase 3 pivotal). Here at Novocure, cancer patients and their families are – and have always been – at the core of our mission. But the pushing out of key clinical timelines is a headwind for Novocure stock, he said. The Clinical Trial Communications Associate is responsible for supporting the Clinical Operations department in advancement of the company’s clinical program. Dr. Kirson has global responsibility for Novocure’s preclinical and clinical and product development programs, as well as the company’s regulatory strategy. Hepatocellular carcinoma is the most widespread type of cancer that originates from the liver. Novocure is the sponsor of clinical trials testing TTFields in several cancers. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in mesothelioma, brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and … Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, … Limited by federal law to investigational use only. A free inside look at Novocure salary trends based on 24 salaries wages for 20 jobs at Novocure. Novocure has ongoing or completed clinical trials … TTFields are delivered to the region of the tumor using a portable medical device for continuous, home use. Eilon Kirson, Novocure’s former Chief Science Officer and Head of Research and Development, visited Dr. Vymazal in 2004 at Na Homolce Hospital in Prague, where Dr. Vymazal worked as a clinical neurologist and radiologist, to discuss running a clinical trial … The incidence of pancreatic cancer is 54,000 new cases annually in the United States, approximately 130,000 new cases annually in Europe, and approximately 39,000 new cases annually in Japan. Description: The Clinical Trial Associate supports the Clinical Trial Manager and Study Team with all operational and trial related activities from study start-up to close out.. We sponsor clinical trials of Tumor Treating Fields in several cancer types. Roza Shnayderman, Head of Novocure’s Israel Biology Lab, joined Novocure in March 2000. Preclinical and clinical data continue to suggest broad applicability of the mechanism of action behind TTFields, and … Phase III study of TTFields combined with chemotherapy for newly-diagnosed pancreatic cancer  more... A phase III study of TTFields following Stereotactic Radiosurgery for 1-10 Brain Metastases from Non-Small-Cell Lung Cancer  more... TTFields have been approved by FDA for the treatment of adult patients suffering from newly diagnosed and recurrent glioblastoma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, … clinical trials Our mechanism of action is broadly applicable across a variety of solid tumors. Broad applicability of the mechanism of action. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and liver cancer. Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New Hampshire, Malvern, Pennsylvania and New York City. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer and … novocuretrial.com The science of Tumor Treating Fields extends beyond glioblastoma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer and … The system applies TTFields non-invasively, and was designed to allow patients to maintain their lifestyle while receiving TTFields. The China expansion is in the initial stages and NovoCure … The incidence of liver cancer is approximately 42,000 new cases annually in the U.S., approximately 82,000 new cases annually in Europe, and approximately 42,000 new cases annually in Japan. novocuretrial.com The science of Tumor Treating Fields extends beyond glioblastoma. Novocure is developing TTFields for different cancer diseases, such as: pancreatic cancer, ovarian cancer, lung cancer, mesothelioma and brain metastasis. annually in Japan. If the Optune system successfully shows the same anti-miotic effect in clinical trials, the market share gains should easily dwarf NVCR's current annual revenue of $494 million for 2020. Of the 214,000 Americans diagnosed with lung cancer annually, only 18% are alive five years later. A phase III study of TTFields combined with chemotherapy for advanced Non-Small-Cell Lung Cancer. This is a full-time, exempt, field-based position that reports to the Clinical Trial … The study is a prospective, randomized controlled phase III trial, to test the efficacy, safety and neurocognitive outcomes of advanced NSCLC patients, following stereotactic radiosurgery (SRS) for 1 … TTFields are delivered to the region of the tumor using a portable medical device for continuous, home use. The Clinical Trial Communications Associate will focus on writing and editing communications materials for our clinical trial efforts, including the website, patient/site-facing materials, and indirect channels in order to increase awareness of the … Tumor Treating Fields is experimental for the treatment of patients with brain metastases, ovarian carcinoma, pancreatic adenocarcinoma, mesothelioma and non-small cell lung cancer. “There … About NSCLC: Lung cancer is the most common cause of cancer-related death worldwide, and non-small cell lung cancer accounts for approximately 85% of all lung cancers. During her seventeen years with Novocure, she and the preclinical team have researched the effects of TTFields on a variety of solid tumor cancer cell lines and laid the foundation for Novocure’s expansion into additional clinical trials.